Clinical Trial Update: Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) [Phase 2]

View source ↗

Summary

Phase 2 results update reporting efficacy, safety and PK/PD of MOR202 in anti-PLA2R positive membranous nephropathy (NewPLACE).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glomerulonephritis
• Membranous Nephropathy

Drugs mentioned

• MOR202

Snippet

Sponsor: HI-Bio, A Biogen Company | Conditions: Glomerulonephritis, Membranous Nephropathy | Phase 2 | Status: COMPLETED